The NADIM-ADJUVANT trial is an open-label, randomized, two-arm, phase III, multicenter clinical trial (47) that was launched in January 2021 with an expected completion date of April 2028. A total of 210 participants (stage IB-IIIA NSCLC without EGFR mutations or ALK rearrangements) are estimated to be recruited. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.